Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …

The epidermal growth factor receptor (EGFR) pathway is a well-studied oncogenic pathway
in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15 …

Objective As a negative regulator of T cells, Programmed Death Ligand 1 (PD-L1) is both an
indicator and inhibitor of anti-tumor immune responses, which has led to confusion about its …

Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …

Abstract Programmed death-ligand 1 (PD-L1) is expressed in various immune cells and
tumor cells, and is able to bind to PD-1 on T lymphocytes, thereby inhibiting their function. At …

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer
(NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) …

Immunity developed to defend our bodies from foreign particles, including bacteria and
viruses. Although effector cells responsible for acquired immunity, mainly T cells, and B …

Blockade of the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)
axis using antibodies against the associated receptors and ligands has yielded good clinical …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Cancer immunotherapy has made great strides in the recent decade, especially in the area
of immune checkpoint blockade. The outstanding efficacy, prolonged durability of effect, and …